Collaboration with Janssen Biotech, Inc. (Details) - Collaborative arrangement - USD ($) $ in Millions |
1 Months Ended | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|---|
Dec. 31, 2011 |
Sep. 30, 2016 |
Sep. 30, 2015 |
Sep. 30, 2016 |
Sep. 30, 2015 |
|
Collaborative and license agreements | |||||
Share of collaboration development costs responsible by the entity (as a percent) | 40.00% | ||||
AbbVie cost sharing expense | $ 70 | $ 65 | $ 195 | $ 87 | |
Non-US | |||||
Collaborative and license agreements | |||||
Collaboration revenues – International | 64 | 37 | 175 | 47 | |
Janssen Biotech, Inc | |||||
Collaborative and license agreements | |||||
Share of collaboration development costs responsible by Janssen (as a percent) | 60.00% | ||||
Janssen Biotech, Inc | United States | |||||
Collaborative and license agreements | |||||
AbbVie profit share costs – United States | $ 211 | $ 124 | $ 540 | $ 169 | |
Pharmacyclics Inc | Janssen Biotech, Inc | |||||
Collaborative and license agreements | |||||
Milestone payments | $ 200 |